Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
暂无分享,去创建一个
J. Verschuuren | M. D. de Baets | M. Losen | P. Martinez-Martinez | S. M. van der Maarel | K. Straasheijm | R. Klooster | J. Plomp | A. Verrips | Jaap J Plomp | Aad Verrips | E. Niks | Silvère M van der Maarel | P. Hermans | F. Detmers | Jan J Verschuuren | Rinse Klooster | Maartje G Huijbers | Erik H Niks | Kirsten R Straasheijm | Frank J Detmers | Pim W Hermans | Kevin Sleijpen | Mario Losen | Pilar Martinez-Martinez | Marc H De Baets | M. Huijbers | K. Sleijpen
[1] W. W. Hofmann,et al. An electrophysiological investigation of neuro‐muscular transmission in myasthenia gravis , 1964, The Journal of physiology.
[2] A. Engel,et al. HISTOMETRIC ANALYSIS OF THE ULTRASTRUCTURE OF THE NEUROMUSCULAR JUNCTION IN MY ASTHENIA GRAVIS AND IN THE MYASTHENIC SYNDROME * , 1971, Annals of the New York Academy of Sciences.
[3] K L Magleby,et al. A quantitative description of end‐plate currents , 1972, The Journal of physiology.
[4] A. Engel,et al. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.
[5] J. Harris,et al. The relationship between end‐plate size and transmitter release in normal and dystrophic muscles of the mouse. , 1979, The Journal of physiology.
[6] R. Miledi,et al. On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end‐plates. , 1980, The Journal of physiology.
[7] A. R. Martin,et al. Non‐linear summation of end‐plate potentials in the frog and mouse. , 1981, The Journal of physiology.
[8] A. Vincent,et al. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. , 1982, Clinical and experimental immunology.
[9] J. Fiekers. Interactions of edrophonium, physostigmine and methanesulfonyl fluoride with the snake end-plate acetylcholine receptor-channel complex. , 1985, The Journal of pharmacology and experimental therapeutics.
[10] M. Neuberger,et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.
[11] S. Nagataki,et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end‐plate in minimal myasthenia gravis , 1989, Neurology.
[12] R. Balderas,et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). , 1989, The New England journal of medicine.
[13] J. Plomp,et al. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha‐bungarotoxin‐treated rats. , 1992, The Journal of physiology.
[14] R. Maselli,et al. Analysis of anticholinesterase‐induced neuromuscular transmission failure , 1993, Muscle & nerve.
[15] K. Campbell,et al. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex , 1995, Neuron.
[16] P. Distefano,et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: Expression in embryonic muscle, at the neuromuscular junction, and after injury , 1995, Neuron.
[17] D. Greiner,et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.
[18] P. Molenaar,et al. Acetylcholine release in myasthenia gravis: Regulation at single end‐plate level , 1995, Annals of neurology.
[19] J. Sanes,et al. Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin β2 , 1995, Nature.
[20] S. J. Wood,et al. The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast‐ and slow‐twitch muscles. , 1997, The Journal of physiology.
[21] G. Fischbach,et al. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. , 1997, Science.
[22] R. Griggs,et al. Mode Switching Kinetics Produced by a Naturally Occurring Mutation in the Cytoplasmic Loop of the Human Acetylcholine Receptor ε Subunit , 1998, Neuron.
[23] T. Eken. Spontaneous electromyographic activity in adult rat soleus muscle. , 1998, Journal of neurophysiology.
[24] G. Yancopoulos,et al. Cloning and Characterization of Muscle-Specific Kinase in Chicken , 2000, Molecular and Cellular Neuroscience.
[25] S. J. Wood,et al. Safety factor at the neuromuscular junction , 2001, Progress in Neurobiology.
[26] A. Vincent,et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.
[27] G. Davis,et al. Maintaining the stability of neural function: a homeostatic hypothesis. , 2001, Annual review of physiology.
[28] K. A. Wall,et al. Split Tolerance in a Novel Transgenic Model of Autoimmune Myasthenia Gravis1 , 2002, The Journal of Immunology.
[29] V. Murthy,et al. Synaptic gain control and homeostasis , 2003, Current Opinion in Neurobiology.
[30] P. Tonali,et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.
[31] A. Engel,et al. Are MuSK antibodies the primary cause of myasthenic symptoms? , 2004, Neurology.
[32] A. Vincent,et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis , 2004, Annals of neurology.
[33] C. Legay,et al. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction , 2004, The Journal of cell biology.
[34] J. Cartaud,et al. The synaptic muscle‐specific kinase (MuSK) complex: New partners, new functions , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.
[35] A. Vincent,et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody–positive myasthenia gravis , 2005, Annals of neurology.
[36] M. Oshima,et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK) , 2006, Journal of Neuroimmunology.
[37] L. Fradkin,et al. Dystrophin Is Required for Appropriate Retrograde Control of Neurotransmitter Release at the Drosophila Neuromuscular Junction , 2006, The Journal of Neuroscience.
[38] Y. Abe,et al. Induction of myasthenia by immunization against muscle-specific kinase. , 2006, The Journal of clinical investigation.
[39] A. Vincent,et al. Single‐fiber electromyography in limb and facial muscles in muscle‐specific kinase antibody and acetylcholine receptor antibody myasthenia gravis , 2006, Muscle & nerve.
[40] S. Dryer,et al. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis , 2006, Neuroscience.
[41] M. Missler,et al. α-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction , 2006, Neuroscience.
[42] P. Matthews,et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. , 2006, Brain : a journal of neurology.
[43] F. Lee,et al. Single-Cell Characterization of Retrograde Signaling by Brain-Derived Neurotrophic Factor , 2006, The Journal of Neuroscience.
[44] R. Flink,et al. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody , 2006, Muscle & nerve.
[45] G. Wolfe,et al. Repetitive nerve stimulation of facial muscles in musk antibody–positive myasthenia gravis , 2006, Muscle & nerve.
[46] B. A. Hesser,et al. Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK , 2006, Molecular and Cellular Neuroscience.
[47] A. Vincent,et al. Strong association of MuSK antibody–positive myasthenia gravis and HLA-DR14-DQ5 , 2006, Neurology.
[48] P. Parren,et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.
[49] D. Zillikens,et al. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases , 2007, Archives of Dermatological Research.
[50] Rob C. G. van de Ven,et al. Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a‐mutant mouse rolling Nagoya , 2007, The European journal of neuroscience.
[51] A. Vincent,et al. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. , 2007, The American journal of pathology.
[52] K. Shigemoto,et al. Clinical and experimental features of MuSK antibody positive MG in Japan , 2007, European journal of neurology.
[53] S. Hubbard,et al. Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSK , 2008, Cell.
[54] J. Linnoila,et al. A Mammalian Homolog of Drosophila Tumorous Imaginal Discs, Tid1, Mediates Agrin Signaling at the Neuromuscular Junction , 2008, Neuron.
[55] A. Vincent,et al. Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies , 2008, Annals of the New York Academy of Sciences.
[56] L. Mei,et al. LRP4 Serves as a Coreceptor of Agrin , 2008, Neuron.
[57] O. Gervásio,et al. Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junction , 2008, Annals of neurology.
[58] F. Dekker,et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1 , 2008, Journal of Neuroimmunology.
[59] J. Verschuuren,et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. , 2008, Brain : a journal of neurology.
[60] T. Rispens,et al. Immunoglobulin G4: an odd antibody , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[61] L. Schaeffer,et al. Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding , 2009, Neurobiology of Disease.
[62] A. Vincent,et al. The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. , 2009, The American journal of pathology.
[63] R. Baines,et al. Chapter The Roles of the Dystrophin-Associated Glycoprotein Complex at the Synapse , 2011 .
[64] Megan R. Carey,et al. Activity-Dependent Regulation of Synapses by Retrograde Messengers , 2009, Neuron.
[65] A. Kokla,et al. Epidemiological and immunological profile of muscle‐specific kinase myasthenia gravis in Greece , 2009, European journal of neurology.
[66] J. Verschuuren,et al. Pre‐ and postsynaptic neuromuscular junction abnormalities in musk myasthenia , 2010, Muscle & nerve.
[67] L. Mei,et al. To build a synapse: signaling pathways in neuromuscular junction assembly , 2010, Development.
[68] T. Gillingwater,et al. Using mouse cranial muscles to investigate neuromuscular pathology in vivo , 2010, Neuromuscular Disorders.
[69] R. Gold,et al. Plasmapheresis for neuroinflammatory disorders , 2010 .
[70] S. Ngo,et al. Patient autoantibodies deplete postsynaptic muscle‐specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice , 2010, The Journal of physiology.
[71] J. Palace,et al. Clinical aspects of myasthenia explained , 2010, Autoimmunity.
[72] S. Kalled,et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype , 2011, Current opinion in rheumatology.
[73] A. Masuda,et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK , 2011, Neurology.
[74] Shuo Lin,et al. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice , 2011, Experimental Neurology.
[75] D. Sanders,et al. Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts , 2011, Muscle & nerve.